Copeland Capital Management’s iRadimed IRMD Stock Holding History

Copeland Capital Management’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.6M	Sell	359,325 -53,225	-13%	-$5.32M	0.77%	50
2025 Q4	$40.1M	Sell	412,550 -20,950	-5%	-$1.8M	0.9%	45
2025 Q3	$30.8M	Sell	433,500 -24,419	-5%	-$1.63M	0.64%	63
2025 Q2	$27.4M	Sell	457,919 -32,625	-7%	-$1.79M	0.56%	75
2025 Q1	$25.7M	Buy	490,544 +14,981	+3%	+$842K	0.52%	78
2024 Q4	$26.2M	Buy	475,563 +53,138	+13%	+$2.8M	0.49%	82
2024 Q3	$21.2M	Buy	422,425 +1,433	+0.3%	+$66.1K	0.37%	93
2024 Q2	$18.5M	Buy	420,992 +2,843	+0.7%	+$121K	0.35%	99
2024 Q1	$18.4M	Buy	418,149 +417,302	+49,268%	+$18.4M	0.33%	93
2023 Q4	$40.2K	Buy	847 +182	+27%	+$7.65K	﹤0.01%	149
2023 Q3	$29.5K	Buy	+665	New	+$30.9K	﹤0.01%	174

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Copeland Capital Management's IRMD Position: Q1 2026 in Review

Copeland Capital Management reduced its iRadimed (IRMD) stake by 13% in Q1 2026, selling an estimated $5.32M and leaving 359,325 shares worth $34.6M. The position accounts for 0.77% of the portfolio, ranked #50.

Copeland Capital Management first reported a position in IRMD in Q3 2023 and has held it in 11 quarters since. The position peaked at $40.1M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Copeland Capital Management held 359,325 shares of iRadimed worth $34.6M as of Q1 2026.
Copeland Capital Management sold 53,225 iRadimed shares in Q1 2026, an estimated $5.32M.
iRadimed made up 0.77% of Copeland Capital Management's portfolio in Q1 2026, its #50 holding.
Copeland Capital Management first reported a position in iRadimed in Q3 2023 and has held it in 11 quarters since.
Copeland Capital Management's iRadimed position peaked at $40.1M in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Copeland Capital Management's 13F filing for Q1 2026, filed 6 May 2026.